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ABSTRACT 
 
Pituitary 18F-FDG uptake correlates with serum TSH levels in subjects with 
diffuse thyroid 18F-FDG uptake 
 
Yong Hyu Jeong 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Mijin Yun) 
 
Purpose:  The aim of this study was to evaluate the relationship among FDG uptake 
in the pituitary gland (FDGp), FDG uptake in the thyroid gland (FDGt), and serum 
thyroid-stimulating hormone (TSH) levels in patients with diffuse FDGt incidentally 
noted on positron emission tomography/computed tomography (PET/CT) scan.  
Materials and Methods:  This retrospective study was approved by our institutional 
review board. We retrospectively reviewed FDG PET/CT scans of 2,945 subjects who 
underwent health screening. Of these, 44 subjects had diffuse FDGt and available 
thyroid function tests. FDGt and FDGp were correlated with serum TSH. FDGp in 44 
paired control subjects without FDGt and 15 thyroid cancer patients undergoing 
thyroid hormone withdrawal were additionally measured, and compared with FDGp 
in the 44 subjects with FDGt divided into three groups according to serum TSH levels.  
Results:  In the 44 subjects, there was a statistically significant (p=0.034) but weak 
correlation(r=0.320) between FDGt and TSH. On the other hand, a strong correlation 
was found between FDGp and TSH (p<0.001, r=0.618). As well, there were 
statistically significant differences in FDGp between the low, normal, and high TSH 
groups (p<0.001). FDGp in the paired control subjects was not different from that in 
the normal TSH group (p=0.384), and FDGp in the TSH-stimulated thyroid cancer 
2 
patients was not different from that in the high TSH group (p=0.463).  
Conclusion:  In this study, we found a strong positive correlation between the 
degree of pituitary FDG uptake and serum TSH. It appears that FDG uptake in the 
pituitary gland holds an important clue to the functional status of the thyroid in 
subjects with diffuse thyroid FDG uptake. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------- -------------------------- 
Key words : diffuse uptake, 
18
F-fluoro-2-deoxy-D-glucose positron emission tomography (
18
F-
FDG PET), pituitary gland, thyroid gland 
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I. INTRODUCTION  
 
With the widespread use of 18F-fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT) for evaluation of oncologic patients, 
various physiological and benign pathologic conditions associated with increased 
FDG uptake have been recognized
1-4
. Among them, one of the common findings is 
focal or diffuse FDG uptake in the thyroid gland (FDGt). Focal FDGt, if incidentally 
detected, raises the possibility of malignancy
5,6
 while it increases the risk of 
aggressiveness if associated with proven differentiated thyroid cancer
7
. On the other 
hand, diffuse FDGt has often been found to be related to benign pathologies, such as 
chronic Hashimoto’s thyroiditis, Graves’ disease, or infrequently multinodular goiter8-
10
. However, one third of diffuse FDGt was considered as a normal variant since the 
patients had a normal thyroid on ultrasound examination with euthyroidism and 
negative autoantibodies
10
. It is currently unknown whether these patients without 
clinical or laboratory abnormalities will eventually develop hypothyroidism. 
Although the exact mechanism for diffuse FDGt is not clear yet, it has mostly been 
attributed to inflammatory cells, especially lymphocytic infiltration, glandular cell 
proliferation, or active fibrotic changes in the thyroid
10-12
. Therefore, investigators 
4 
have attempted to predict the functional status of the thyroid gland by correlating 
standardized uptake values (SUVs) of diffuse FDGt with the level of serum thyroid-
stimulating hormone (TSH). When compared to controls without diffuse thyroid 
uptake, patients with diffuse FDGt have increased serum TSH
12
. However, maximum 
SUV (SUVmax) of FDGt was not predictive of serum TSH levels among patients with 
diffusely increased FDGt
11
.  
Recently, we noticed various degrees of FDG uptake in the pituitary gland (FDGp) 
on PET/CT in patients with diffuse FDGt. Since the secretion of TSH from the 
pituitary gland is tightly regulated by the circulating thyroid hormone level, we 
hypothesized that FDGp is related to the functional status of thyroid gland and/or 
TSH. We assessed the relationship among FDGp, FDGt, and TSH. 
 
II.  MATERIALS AND METHODS  
 
1. Patient Population 
This retrospective study was approved by our institutional review board. Two 
imaging specialists reviewed the FDG PET/CT scans performed on 2,945 subjects for 
health screening from May 2006 to December 2012 in our medical center. Diffuse 
FDGt defined as diffuse uptake in the bilateral thyroid lobes that was greater than 
adjacent background uptake was identified in 180 subjects. Of these, 44 (9 men, 35 
women; age range, 41–86 years; mean age, 57.2 years) satisfied all of the following 
inclusion criteria:  
1. Thyroid function test was performed within 1 month of PET imaging 
2. No prior history of thyroid disease 
3. No known history of other endocrine problems  
4. No prior history of brain surgery 
5. Fully-covered field of view to afford complete evaluation of pituitary gland 
In these 44 subjects, FDGt and FDGp were correlated with serum TSH levels. 
Additionally, we enrolled 44 paired age-and-sex-matched subjects without FDGt as a 
negative control group and 15 patients with metastatic thyroid cancer (4 men, 11 
5 
women; age range, 37–81 years; mean age, 56.5 years) who underwent PET/CT 
following 4 weeks of thyroid hormone withdrawal resulting in TSH stimulation as a 
positive control group. 
 
2. Imaging Procedures 
All subjects fasted for at least 6 h, and blood glucose concentration was confirmed 
to be less than 140 mg/dL before the injection of FDG. Approximately 5.5 MBq of 
FDG per kg of body weight were administered intravenously. Imaging was performed 
using a PET/CT scanner (DSTe; GE Healthcare, Milwaukee, WI, USA) with an axial 
field of view of 15.7 cm and a spatial resolution of 4.0 mm in full width at half 
maximum at 1 cm from the center. Sixty minutes after the FDG injection, a low-dose 
CT scan was obtained for attenuation correction with an 8-slice helical CT unit (Light 
Speed; GE Healthcare) using the following parameters: 140 kVp, 30 mA, 0.8-s 
rotation time, 3.3-mm scan reconstruction, 50-cm field of view, and 512ⅹ512 matrix. 
A PET imaging was followed covering the skull base to the mid-thigh in a three-
dimensional mode at 3 minutes per bed position. PET data were reconstructed 
iteratively using an ordered subset expectation maximization algorithm with the low-
dose CT datasets for attenuation correction. 
 
3. Image and Data Analysis  
For semi-quantitative analysis of FDGt in the 44 subjects and 44 paired-control 
subjects, a total of 6 regions of interest (ROIs) were drawn over the thyroid. Three 
ROIs were placed in the upper, mid, and lower poles in each lobe, respectively. 
SUVmax of each region was recorded and the average of the SUVmax from the 6 ROIs 
was calculated for each patient. For the measurement of SUVmax of FDGp in the 88 
subjects and 15 patients with thyroid cancer, a ROI was drawn over the pituitary fossa, 
which was determined on co-registered transaxial CT images. 
Thyroid function tests were performed within 1 month of PET/CT (mean interval, 
0.6 days; range, 0–25 days) in the all subjects and control groups. Serum TSH and 
free thyroxine (T4) were measured using a chemiluminescent microparticle 
6 
immunoassay (CHIMA; ARCHITECT®  System, Abbott Laboratories Diagnostic 
Division, Abbott Park, IL, USA). Normal reference ranges are 0.35–5.50 µIU/mL for 
TSH and 0.70–1.48 ng/dL for free T4. The 44 subjects were divided into three groups: 
high TSH group (>5.5 µIU/mL), normal TSH group (0.35–5.5 µIU/mL), and low TSH 
group (<0.35 µIU/mL). 
The thyroid SUVmax and the pituitary SUVmax in the 44 subjects with diffuse FDGt 
were directly correlated with serum TSH levels. Additionally, the SUVmax of the 
pituitary gland in the negative or positive control group was compared with that of the 
pituitary gland in the low, normal, and high TSH groups.  
 
4. Statistical Analysis 
A correlation between pituitary or thyroid SUVmax and serum TSH levels in the 44 
subjects was assessed using Spearman’s rank correlation analysis. 
Kruskal–Wallis test and Dunn’s post-hoc analysis were performed to determine 
the differences in SUVmax among the high, normal, and low TSH groups. The 
pituitary SUVmax in the normal paired-subjects and TSH-stimulated patients groups 
were compared with that in each of the high TSH, normal TSH, and low TSH 
groups using Mann–Whitney U-test. All statistical computations were performed 
using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA) and a p-value < 0.05 was 
considered statistically significant.  
 
III. RESULTS 
 
In the 44 subjects with diffuse FDGt who underwent PET/CT for health screening, 
the thyroid SUVmax ranged from 1.80 to 9.00 (median, 3.15), the pituitary SUVmax 
ranged from 1.70 to 4.50 (median, 2.80), and the serum TSH ranged from 0.03 to 
159.63 µIU/mL (median, 2.86 µIU/mL). There was a statistically significant but 
only marginal correlation (Fig. 1a; p = 0.03, r = 0.320) between the thyroid SUVmax 
and TSH level. On the other hand, a strong correlation was found between FDGp 
and TSH (Fig. 1b; p < 0.001, r = 0.618). 
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Fig. 1 SUVmax of thyroid gland (a, c) and pituitary gland (b, d) on PET/CT. Side by 
side box plots of SUVmax by each groups and Spearman’s rank analysis. Statistically 
significant differences were found in SUVmax of pituitary gland between groups, but 
not in SUVmax of thyroid gland. 
 
When the 44 subjects were divided into three groups according to the reference 
TSH ranges, there were 12 subjects (27%) in the high TSH group, 27 subjects (61%) 
in the normal TSH group, and 5 subjects (12%) in the low TSH group. The free T4 
level in the high TSH group was 1.01 ± 0.39 μIU/mL (median ± interquartile range), 
1.10 ± 0.15 μIU/mL in the normal TSH group, and 1.23 ± 0.88 μIU/mL in the low 
TSH group. Free T4 levels between the three groups were significantly different (p 
= 0.01). The clinical characteristics and results of thyroid function test in those three 
groups are summarized in Table 1. 
 
8 
Table 1 Characteristics of subjects according to serum TSH concentration 
 
Serum TSH concentration (μIU/mL) 
p 
<0.35 0.35–5.5 >5.5 
Patients (no.) 5 27 12  
Sex (no.)    0.5 
Male 
Female 
1 
4 
7 
20 
1 
11 
 
Age (years) 55.4 ± 6.2 58.5 ± 10.7 54.9 ± 7.8 0.5 
TSH (μIU/mL)     
Median 
Interquartile range 
0.11 
0.07–0.25 
2.26 
1.39–3.46 
9.45 
6.96–38.43 
 
Free thyroxine 
(ng/dL) 
Median 
Interquartile range 
 
1.23 
1.19–1.80 
 
1.10 
0.99–1.13 
 
1.01 
0.76–1.07 
0.001 
 
 
Data are expressed as mean ± SD, median and interquartile range, or the number of 
patients in each group. 
 
The thyroid SUVmax was 2.50 ± 1.30 in the low TSH group, 3.10 ± 1.50 in the 
normal TSH group, and 4.10 ± 2.10 in the high TSH group. Despite the trend, there 
was no statistically significant difference in SUVmax of the thyroid gland between 
these groups (Table 2 and Fig. 1c; p = 0.1 by Kruskall–Wallis test). In contrast, the 
pituitary SUVmax was 2.10 ± 0.55 in the low TSH group, 2.80 ± 0.50 in the normal 
TSH group, and 3.40 ± 1.25 in the high TSH group. The median values of SUVmax 
of the pituitary gland were significantly different among the three groups (Table 2; p 
< 0.001). Dunn’s post-hoc test also showed statistically significant differences in 
SUVmax between low and normal TSH groups, low and high TSH groups, and 
normal and high TSH groups (Fig. 1d; p = 0.03, <0.001, and 0.030, respectively).  
All 44 paired negative control subjects had normal TSH levels (median, 1.53; 
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interquartile range, 1.35) and a median FDGp of 2.70 ± 0.33. There was no difference 
in FDGp between the negative control group and the normal TSH group (p = 0.3), 
whereas it was significantly different from the low and high TSH groups (p < 0.001, 
both; Fig. 2 & 3). In the 15 positive control patients, TSH levels were >30 μIU/mL 
(median, 94.64 μIU/mL; interquartile range, 39.25 μIU/mL) for each patient, with a 
median FDGp of 3.20 ± 0.60. There was no difference in FDGp between the positive 
control group and the high TSH level group (p = 0.5), whereas it was significantly 
higher than that in the low and normal TSH groups (p = 0.001 and 0.007, respectively; 
Fig. 2). 
 
Table 2 Comparison of SUVmax in thyroid gland and pituitary gland according to 
serum TSH concentration 
 
Serum TSH concentration (μIU/mL) 
p 
<0.35 0.35–5.5 >5.5 
Pituitary SUVmax 2.10 ± 0.55 2.80 ± 0.50 3.40 ± 1.25 <0.001 
Thyroid SUVmax 2.50 ± 1.30 3.10 ± 1.50 4.10 ± 2.10 0.1 
Data are expressed as median ± interquartile range. 
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Fig. 2 SUVmax of pituitary glands in paired normal thyroid patients and TSH-
stimulated patients. Side by side box plots of SUVmax by each groups. SUVmax of 
pituitary gland in the paired normal thyroid groups was not different from that in the 
normal TSH group, and FDGp in the TSH-stimulated thyroid cancer patients was not 
different from that in the high TSH group. 
 
 
Fig. 3 FDG PET images showing various levels of FDG uptake in the pituitary fossa 
in subjects with different serum TSH levels. (A) Scanty pituitary FDG uptake in a 
subject with low TSH (0.11 μIU/mL); (B) moderate pituitary FDG uptake in a subject 
with normal TSH (3.27 μIU/mL); and (C) intense pituitary FDG uptake in a subject 
with high TSH (9.28 μIU/mL). 
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IV. DISCUSSION 
 
Thyroid gland preferentially uses free fatty acids for energy metabolism and thus 
generally does not show significant FDG uptake on PET
8, 10
. However, diffuse FDGt 
has been seen in 2.9–3.5% of the study population, and even up to 20% in patients 
with breast cancer, suggesting a correlation between thyroid disease and the risk of 
breast cancer
10-13
. In the present study, we found diffuse FDGt in 6.1% of the subjects 
undergoing health screening examinations. 
In patients whose FDGt was considered to be a normal variant, FDGt was less than 
(63.6%) or equal to (22.7%) that of the liver
10
. The mechanism of increased FDGt as a 
normal variant is not known yet. On the contrary, in most (76.9%) patients with 
chronic thyroiditis, FDGt was higher than or equal to the liver uptake. Although 
diffuse intense uptake seemed to have some correlation with hypothyroidism 
compared to normal control, no significant correlation was found between SUVmax of 
the thyroid and the degree of hypothyroidism measured by serum TSH
11
. In our study, 
a marginal correlation was found between the SUVmax of the thyroid and serum TSH. 
The correlation was mildly significant statistically but probably not significant 
enough to be clinically useful. Indeed, there was no significant difference in FDGt in 
the three groups divided by the reference TSH ranges.  
There are known factors affecting FDGt. In chronic thyroiditis, the severity of 
inflammation including lymphocytic infiltration is considered the main reason for the 
increased FDGt
14
. There can be a time lag from the diagnosis of chronic thyroiditis 
with increased FDGt until the sufficient loss of thyroid cells to cause clinically overt 
hypothyroidism
13
. In addition, small, atrophic thyroid as a result of longstanding 
destruction by chronic inflammation may show low uptake but increased serum TSH 
levels. The mixture of different stages of disease pathology might be one of the 
reasons that FDGt is not consistently predictive of serum TSH levels. To make the 
matter more complicated, FDGt may also be seen in patients with the opposite disease 
entities associated with low serum TSH levels, e.g., Graves’ disease or multinodular 
goiter. All of these probably explain why there is no significant correlation or very 
12 
weak correlation, if present, between diffuse FDGt and serum TSH.  
While looking for a potential predictor of thyroid function in subjects with diffuse 
FDGt, we found increased FDGp in many of them. It was conceivable that pituitary 
hyperplasia secondary to hypothyroidism could occur due to the loss of T4 feedback 
inhibition resulting in the over-production of thyrotropin-releasing hormone (TRH)
15-
17
. Indeed, there was a case report showing secondary pituitary hyperplasia with 
increased FDG uptake by adrenal cortical insufficiency
18
. Accordingly, we assessed 
whether FDGp could be a predictor of the functional status of the thyroid gland. The 
pituitary SUVmax was indeed different between each of the three groups with low, 
normal, and high TSH levels. More significantly, there was a strong positive 
correlation between the continuous SUVmax values of the pituitary gland and serum 
TSH levels. The finding supports our hypothesis that FDGp is related to the 
functional status of thyroid gland and/or TSH. FDGp may be an imaging 
representative of physiologic regulation status of hypothalamus–pituitary–thyroid axis 
in subjects with diffuse FDGt and no other known endocrine disorders. This was 
further supported by FDGp in the two control groups. In the negative control group, 
FDGp was no different from that of the normal TSH group, whereas it was 
significantly different from that in the low and high TSH groups. FDGp in the 
positive control group was as high as FDGp in the high TSH group, but significantly 
higher than FDGp in the low and normal TSH groups. 
Our study has some limitations. Although we tried to exclude those with known 
history of any endocrine disease, we had limited data regarding other hormonal 
profiles in the subjects. Therefore, we did not evaluate the effect of hormones other 
than thyroid hormones in FDG uptake in the pituitary gland. 
 
V. CONCLUSION 
 
While diffuse thyroid uptake of FDG was marginally correlated with serum TSH 
levels, we found a strong positive correlation between the degrees of FDG uptake in 
the pituitary gland and serum TSH levels. FDG uptake in the pituitary gland appears 
13 
to hold an important clue to the functional status of the thyroid in subjects with 
diffuse thyroid FDG uptake. Those subjects with abnormal pituitary FDG uptake 
could be offered a further evaluation of thyroid function test. 
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ABSTRACT (IN KOREAN) 
 
양전자방출단층촬영술 시행 시 갑상샘의 미만성 FDG 섭취를 보이는 
환자에서 우연적 뇌하수체의 FDG 섭취 정도와 혈중 갑상선 자극 
호르몬 농도의 관계 파악 및 그에 따른 임상적 유용성 
 
<지도교수 윤미진> 
 
연세대학교 대학원 의학과 
 
정용휴 
 
연구목적: 양전자방출단층촬영 시행 시에 우연히 발견된 미만성 갑상선 
섭취 환자에서 뇌하수체의 과증식으로 인한 FDG 섭취 증가 정도와 혈중 
갑상선 자극 호르몬 농도와의 연관성을 알아보고 이에 대한 임상적 의미를 
알아 보고자 하였다. 
대상 및 방법: 2006년 5월부터 2012년 12월까지 신촌세브란스 병원에서 
건강검진을 목적으로 양전자방출단층촬영술을 시행한 사람 중 미만 성 
갑상선 섭취 증가를 보이는 44명을 대상으로 갑상선 및 뇌하수체의 FDG 
섭취와 갑상선 자극 호르몬 농도를 비교하였으며, 검증을 위해 갑상선 
섭취증가를 보이지 않는 44명의 음성 대조군과 방사성 옥소 치료를 위해 
인위적으로 갑상선 자극 호르몬 수치를 높인 15명의 양성 대조군을 
설정하였다. 
결과: 44명의 대상자에서 갑상선의 FDG 섭취와 갑상선 자극 호르몬 
농도는 약한 상관관계(p=0.034, r=0.320)를 보인 것에 반해 뇌하수체의 
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FDG 섭취와 갑상선 자극 호르몬 농도는 더 강한 상관관계를 보였다 
(p<0.001, r=0.618). 또한, 갑상선 자극 호르몬의 농도에 따라 갑상선 기능 
저하, 정상, 갑상선 기능 항진 세 군으로 나눴을 때 각 군의 뇌하수체의 
FDG 섭취는 유의한 차이를 보였다(p<0.001). 음성 대조군 44명의 
뇌하수체의 FDG 섭취는 정상 갑상선 기능 군과(p=0.384), 양성 대조군 
15명의 뇌하수체의 FDG 섭취는 갑상선 기능 항진 군과(p=0.463) 차이가 
없어 본 결과를 뒷받침 해주었다. 
결론:  미만 성 갑상선 섭취를 보이는 환자에서 뇌하수체의 FDG 섭취는 
갑상선 자극 호르몬 농도와 밀접한 관계가 있으며, 이는 뇌하수체의 FDG 
섭취를 통해 환자의 갑상선 기능을 평가할 수 있음을 나타낸다. 
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